In this study, we investigated adaptive mechanisms associated with aromatase inhibitor (AI) resistance in breast cancer cells and show that sensitivity to AIs can be extended through dual inhibition of estrogen receptor (ER) and human epidermal receptor-2 (Her-2) signaling. We used human ER-positive breast cancer cells stably transfected with the aromatase gene (MCF-7Ca). These cells grow as tumors in nude mice and are inhibited by AIs. Despite continued treatment, tumors eventually become insensitive to AI letrozole. The cells isolated from these long-term letrozole-treated tumors (LTLT-Ca) were found to have decreased ERA levels. Our results suggest that LTLT-Ca cells survive estrogen deprivation by activation of Her-2/mitogen-activated protein kinase (MAPK) pathway. Here, we show that trastuzumab (antibody against Her-2; IC 50 = 0.4 mg/mL) was very effective in restoring the ERA levels and sensitivity of LTLT-Ca cells to endocrine therapy by down-regulation of Her-2/MAPK pathway and up-regulation of ERA. In contrast, trastuzumab was ineffective in the parental hormone-responsive MCF-7Ca cells (IC 50 = 4.28 mg/mL) and xenografts. By blocking Her-2, trastuzumab also up-regulates ERA and aromatase expression and hypersensitized MCF-7Ca cells to E 2 . We show that trastuzumab is beneficial in hormone-refractory cells and xenografts by restoring ER, implicating Her-2 as a negative regulator of ERA. In xenograft studies, the combination of trastuzumab plus letrozole is equally effective in inhibiting growth of MCF-7Ca tumors as letrozole alone. However, on the acquisition of resistance and increased Her-2 expression, the combination of letrozole plus trastuzumab provided superior benefit over letrozole or trastuzumab alone.
Introduction
Aromatase inhibitors (AI) such as letrozole and anastrozole that reduce estrogen production have now been shown to be more effective than antiestrogen (AE) tamoxifen in estrogen receptorpositive (ER + ) breast cancer patients and have few side effects. Nevertheless, not all patients respond and resistance to treatment may eventually occur in others. To investigate the mechanisms involved in the loss of sensitivity of the tumors to AIs, we developed a cell line isolated from tumors of human ER + breast cancer cells (MCF-7) stably transfected with aromatase (MCF-7Ca) grown in mice treated with letrozole for an extended period of time (1) (2) (3) . We have previously reported that during treatment with letrozole, MCF-7Ca xenografts up-regulate human epidermal receptor-2 (Her-2) and proteins in the downstream mitogenactivated protein kinase (MAPK) signaling pathway (1) . These cells also exhibited lower expression of ERa and apparent ''estradiolindependent'' growth. We have also shown that signaling pathways, such as the Her-2/MAPK, are key regulators of the growth of letrozole-refractory cells (1, 4) . Similarly, several other investigators have reported the importance of members of epidermal growth factor receptor (EGFR) family (Her-2/EGFR) in resistance to endocrine therapy (5) (6) (7) (8) . We and others have suggested that the combination of EGFR/Her-2 tyrosine kinase inhibitors or trastuzumab (monoclonal humanized antibody against Her-2, Herceptin) in combination with AIs or AEs may delay acquisition of resistance (4, (9) (10) (11) (12) (13) .
In this study, we investigated the effects of trastuzumab on the growth of letrozole-refractory breast cancer cells. On examination, MCF-7Ca-derived tumors treated with letrozole up-regulated Her-2 4 weeks into treatment despite continued responsiveness to letrozole. Moreover, the level of Her-2 protein was found to be 6-fold higher in letrozole-refractory tumors than the control tumors (1) . However, when Her-2 was inhibited, ERa levels were restored. This suggests that Her-2 is a negative regulator of ERa. This observation led to our hypothesis that inhibition of both the Her-2 and estrogen signaling pathways is required to prolong the responsiveness of the tumors to endocrine therapies (14, 15) .
Thus, the combination of an AI plus Her-2 inhibitor could provide a substantial benefit in tumor growth inhibition when used after the acquisition of letrozole resistance.
Duarte, CA). Letrozole was provided by Dr. D. Evans (Novartis Pharma, Basel, Switzerland). The pure AE fulvestrant and anastrozole were supplied by Dr. E. Anderson (AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom).
Cell culture. MCF-7Ca cells were routinely cultured in DMEM supplemented with 5% fetal bovine serum, 1% penicillin/streptomycin, and 700 Ag/mL G 418 . LTLT-Ca cells were developed from MCF-7Ca cells as described earlier from tumors of mice treated with letrozole for 56 wk (1) . The cells were maintained in steroid-depleted medium, which consisted of phenol red-free IMEM supplemented with 5% dextran-coated charcoaltreated serum, 1% penicillin/streptomycin, and 750 Ag/mL G 418 and 1 Amol/L letrozole. Cell proliferation assays were performed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described earlier (4) . The results were expressed as a percentage of the cell number in the D 4 A-treated control wells. IC 50 values for inhibitors were calculated from the linear regression line of the plot of percentage inhibition versus log inhibitor concentration.
Tumor growth in ovariectomized female athymic nude mice. All animal studies were performed according to the guidelines and approval of the Animal Care Committee of the University of Maryland, Baltimore. Female ovariectomized BALB/c athymic nude mice 4 to 6 wk of age were obtained from the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD). The mice were housed in a pathogen-free environment under controlled conditions of light and humidity and received food and water ad libitum.
The tumor xenografts of MCF-7Ca cells were grown in the mice as previously described (1, 16, 17) . Each mouse received s.c. inoculations in one site per flank with 100 AL of cell suspension containing f2.5 Â 10 7 cells. The mice were injected daily with D 4 A (100 Ag/d). Weekly tumor measurements and treatments began when the tumors reached f300 mm 3 . Mice were assigned to groups for treatment so that there was no statistically significant difference in tumor volume among the groups at the beginning of treatment. Letrozole and D
4
A for injection were prepared in 0.3% hydroxypropylcellulose. Trastuzumab for injection was prepared as 20 mg/mL stock solution in bacteriostatic water for injection and then diluted in 0.9% NaCl solution to obtain the required concentrations. Mice were then injected s.c. five times weekly with the indicated drugs: 100 Ag/mouse/d D A used are as previously determined and reported (1, 2) . Mice in the trastuzumab group received 5 mg/kg/wk of the drug i.p. divided in two doses. Mice in the D 4 A and trastuzumab group were treated for 7 wk, after which they were sacrificed due to large tumor volumes by decapitation and the blood was collected for analysis. The other groups (letrozole, trastuzumab plus letrozole, letrozole switched to trastuzumab plus letrozole, and letrozole switched to trastuzumab) were sacrificed on week 28.
Western blotting. The protein extracts from tumor tissues were prepared by homogenizing the tissue in ice-cold DPBS containing protease inhibitors (18) . A total of 50 Ag protein from each sample was analyzed by SDS-PAGE as described previously (4) . Bands were quantitated by densitometry using Molecular Dynamics Software (ImageQuant). The densitometric values are corrected for loading control.
Competitive binding studies. Binding of trastuzumab to ER in MCF7Ca cells was assessed by competitive binding assay as described before (3). MCF-7Ca cells were transferred to steroid-depleted medium for 1 d before plating for the binding assay. H-E 2 was used as a ligand and nonradiolabeled E 2 was used to determine nonspecific binding. Triamcinolone (1 Amol/L) was used to saturate glucocorticoid receptors.
3 H 2 O release assay for aromatase activity measurement. The radiometric 3 H 2 O release assay was performed as described previously (19) . For pretreatment studies, cells were treated with indicated agent for 24 h before incubating with [1-h 3 H]D 4 A for 18 h. For measuring aromatase activity in tumor samples, the tumors were homogenized in ice-cold DPBS. The resulting homogenate was used for aromatase activity assay (19) . The activity of the enzyme is corrected for protein concentration in the tumor homogenates and cells.
ERA transactivation assay. To measure activation of ERa, an ELISAbased ER transactivation assay was performed as per manufacturer's guidelines (Panomics). Briefly, the nuclear lysates of cells or tumors were generated as described by the manufacturer. Activated ER from nuclear extracts was allowed to bind to an ER consensus binding site (ER probe) on a biotinylated oligonucleotide. These oligonucleotides were then immobilized on a streptavidin-coated 96-well plate. The ER bound to the oligonucleotide is then detected by an antibody directed against ER. An additional horseradish peroxidase-conjugated secondary antibody provided colorimetric readout quantified by reading absorbance at 450 nm.
RNA extraction and reverse transcription. RNA was extracted and purified using the RNeasy Mini kit (Qiagen) as per manufacturer's protocol. Total RNA concentration and purity were determined from 260 and 280 nm absorbances. RNA was diluted with water to 0.08 Ag/AL and reverse transcribed as described by Kazi and colleagues (20) .
PCR. Analysis of ERa, CYP-19, and pS2 mRNA expression was done by conventional PCR. ChIP assay. For in vitro ChIP assay, the treated cells were washed with DPBS and fixed with 1% formaldehyde/DPBS for 10 min at 37jC, after which the cells were washed with ice-cold DPBS containing protease inhibitors. The cells were collected into 1 mL DPBS and pelleted by centrifugation at 6,000 rpm for 5 min at 4jC. The cell pellet was resuspended in nuclear lysis buffer (ChIP kit, Upstate) and incubated on ice for 15 min.
For in vivo ChIP assay, tumor slices were immersed in 2% formaldehyde/ DPBS mixture and incubated at room temperature for 15 min. Fixation was stopped by adding 1 mol/L glycine and incubating for 5 min at room temperature. The tissues were rinsed in ice-cold DPBS containing the protease inhibitor tablet and homogenized on ice in modified radioimmunoprecipitation assay buffer. The tissue homogenate was centrifuged at 12,000 rpm for 5 min at 4jC; the nuclear pellet was resuspended in nuclear lysis buffer and incubated on ice for 15 min. Samples were sonicated on ice for 10 Â 10 s cycles, with 20-s pauses between each cycle. The sonicated samples were centrifuged at 14,000 rpm for 10 min at 4jC. Sonicated samples were diluted 1:10 with dilution buffer (ChIP kit) before being immunocleared in a solution containing protein A-or G-Sepharose slurry (Amersham) in Tris/ EDTA buffer, salmon sperm DNA (Invitrogen), and normal mouse or rabbit serum (Sigma Chemical) for 2 h at 4jC. Immunocleared supernatants were incubated overnight at 4jC with anti-ERa antibody (Santa Cruz Biotechnology). Protein A-or G-Sepharose beads and salmon sperm DNA were then added and incubated for 1 h at 4jC. The beads were then washed sequentially with 1 mL each of wash buffers. The protein-DNA complexes were then eluted by twice incubating beads in elution buffer for 10 min at room temperature with vigorous mixing. To separate immunoprecipitated protein and DNA, the pooled elutes were incubated at 65jC overnight. The DNA was purified using the QIAquick PCR Purification kit (Qiagen). Alternatively, immunoprecipitated ERa on the beads was subjected to Western immunoblotting. The boiled (denatured) protein samples were resolved by SDS-PAGE and membranes were probed for histone H3 and RNA polymerase II.
The yield of target region DNA in each sample after ChIP was analyzed by conventional PCR. The following primers were used for PCR analysis (34 cycles at 60jC annealing temperature): human pS2, Statistics. For in vivo studies, mixed-effects models were used. The tumor volumes were analyzed with S-PLUS (7.0; Insightful Corp.) to estimate and compare an exponential variable (bi) controlling the growth rate for each treatment groups. The original values for tumor volumes were log transformed. In the process of searching for a suitable model, we observed that the piecewise (knot at 15 wk) model fits the data reasonably well (on groups switched after week 15 to another drug). The spline model with a single knot at time = week-15 wk was used to accommodate the nonlinearity with a piece-wise linear model. All P values <0.05 were considered statistically significant. The graphs are represented as mean F SE.
Results
Trastuzumab inhibits growth of LTLT-Ca cells and tumors and down-regulates MAPK activation. Trastuzumab was found to inhibit growth of LTLT-Ca cells in a dose-dependent manner with an IC 50 of 400 Ag/mL (2.75 Amol/L) compared with 4.28 mg/mL (29.41 Amol/L) in parental MCF-7Ca cells (Fig. 1A) .
In LTLT-Ca cells, trastuzumab (100 Ag/mL) also decreased the activation of proteins of the MAPK pathway along with Her-2 in a time-dependent manner (Fig. 1B) . This down-regulation was initiated as early as 15 minutes and was sustained until at least 72 hours. In addition, ERa was nearly restored to the level of the parental MCF-7Ca cells.
To study the effect of trastuzumab in vivo, LTLT-Ca cells were inoculated s.c. into ovariectomized nude mice. The following day, the mice were divided in two groups. One group received letrozole (n = 5) and the other group received vehicle only (control, n = 25). LTLT-Ca xenografts were grown in female OVX nude mice as described in Materials and Methods. The mice in the control and letrozole-treated group exhibited similar rate of tumor growth. The difference in the exponential variable governing growth was À0.027 (P = 0.71) over first 8 wk and 0.001 (P = 0.97) over 19 wk. Four doses of trastuzumab were tested. All of the tested doses caused a marked regression of LTLT-Ca xenografts. The growth rate of tumors of mice treated with trastuzumab (5 mg/kg/wk) was significantly different from mice in the control (P = 0.0008) and letrozole-treated (P = 0.0002) mice. The difference in the exponential variable governing growth between control and trastuzumab was 0.24 (P = 0.0008). The difference in the exponential variable governing growth between letrozole and trastuzumab was 0.27 (P = 0.0002). D, effect of combination of trastuzumab with AEs tamoxifen and fulvestrant and AIs exemestane and anastrozole in LTLT-Ca cells. Viability of cells was measured by MTT assay after 6-d treatment with AEs and AIs in the presence or absence of 100 Ag/mL trastuzumab as described in Materials and Methods. The generalized linear model method was applied to estimate and assess differences among groups' means. The cell viability was found to be significantly lower in treatment groups treated with the combination of trastuzumab plus AI or AE versus control (*, P < 0.0001) or trastuzumab alone (*, P < 0.0001) or the endocrine agent alone (*, P < 0.0001).
When the tumors of the mice in the control group reached f300 mm 3 , this group was regrouped into five (n = 5) and injected with vehicle or 2, 5, 10, and 20 mg/kg/wk of trastuzumab i.p. (divided in two doses). As shown in Fig. 1C , the tumors in all of the trastuzumab-treated groups regressed over the course of the experiment. The dose of 5 mg/kg/wk trastuzumab was selected for future investigations. As shown previously (1), treatment with letrozole did not result in a statistically significant difference in tumor growth than observed in controls (P = 0.91).
Trastuzumab restores sensitivity of LTLT-Ca cells to AEs and AIs. As shown in our earlier studies, LTLT-Ca cells exhibit crossresistance to growth-inhibitory effects of tamoxifen, fulvestrant, exemestane, and anastrozole (1). However, the combination of trastuzumab (100 Ag/mL) with AEs or AIs produced synergistic growth inhibition. As shown in Fig. 1D , the combination of trastuzumab with AE/AI at 1 Amol/L each produced synergistic growth inhibition. The combination was statistically better than either drug alone (P < 0.0001) or control (P < 0.0001), whereas single drug treatment with AE or AI was not statistically different from control. As shown in Fig. 2A , proliferation of LTLT-Ca cells was not inhibited with letrozole (10 À12 to 10 À5 mol/L), whereas cotreatment with trastuzumab (100 Ag/mL) and letrozole inhibited the growth of LTLT-Ca cells in a dose-dependent manner. However, in MCF-7Ca cells, the combination of letrozole plus trastuzumab was not significantly different from letrozole at 10 À9 to 10 À5 mol/L but different from letrozole alone at 10 À12 to 10 À10 mol/L (Fig. 2B) . Although the IC 50 value of letrozole in the presence of trastuzumab was 2-log lower than that in the absence of trastuzumab, it should be noted that this effect was not seen in vivo.
The effect of combining trastuzumab plus letrozole was also examined in letrozole-refractory LTLT-Ca xenografts (data not Figure 2 . A, effect of combination of letrozole and trastuzumab in LTLT-Ca cells. Viability of cells was measured by MTT assay after 6-d treatment with letrozole (10 À12 to 10 À5 mol/L) alone or in the presence of trastuzumab (100 Ag/mL) as described in Materials and Methods. The treatment with the combination of letrozole plus trastuzumab was significantly better than single drug treatment or control. *, P < 0.01 (10 À12 to 10 À9 mol/L); c, P < 0.0001 (10 À8 to 10 À5 mol/L). B, effect of combination of letrozole and trastuzumab in MCF-7Ca cells. Viability of cells was measured by MTT assay after 6-d treatment with letrozole (10 À12 to 10 À5 mol/L) alone or in the presence of trastuzumab (100 Ag/mL) as described in Materials and Methods. Combination of letrozole plus trastuzumab was significantly better than single drug treatment or control. *, P < 0.0001
shown). The tumors of mice receiving trastuzumab plus letrozole regressed significantly in volume. The combination was significantly better than trastuzumab alone (P < 0.0001), letrozole alone (P = 0.0001), and control (P < 0.0001), although trastuzumab alone was significantly better than control (P < 0.0001). These data suggest that combining letrozole plus trastuzumab was significantly more effective than single agent in letrozole-refractory LTLTCa xenografts (26) .
Trastuzumab up-regulated ERA-and E 2 -mediated transcription in LTLT-Ca cells. Treatment with trastuzumab upregulated ERa in LTLT-Ca cells (Fig. 1B) . The maximum increase of ERa was seen at 24 hours and was found to be 0.83-fold compared with basal level of ERa in MCF-7Ca cells. A 10-fold higher level of ERa was found in LTLT-Ca cells compared with basal levels (0.83 compared with 0.08). In addition, trastuzumab pretreatment followed by E 2 treatment for 1 hour increased ER-mediated transcription in a time-dependent manner (Fig. 2C) . A 72-hour pretreatment of LTLT-Ca cells with trastuzumab followed by 1 hour of E 2 treatment induced ERa transcriptional activation to the same extent as in parental MCF-7Ca cells stimulated with E 2 alone.
In vitro ChIP assay and reverse transcription-PCR (RT-PCR) analysis were performed to examine the effect of trastuzumab alone or in combination with E 2 on ERa-mediated transcription.
When stimulated with trastuzumab, MCF-7Ca and LTLT-Ca cells exhibit increased transcriptional activation as evidenced by increase in the expression of pS2 mRNA, a known ERa-responsive gene. This transcriptional activation was found to be dose dependent (Fig. 2D) . In addition to pS2, the transcription of ERa and CYP-19 gene was found to be up-regulated in a dosedependent manner. In vitro ChIP assay was performed to examine recruitment of ERa to the promoter region of pS2 and aromatase gene. The Western blotting for histone H3 confirms recruitment of ERa to the DNA and RNA polymerase II expression confirms transcriptional activation (Fig. 3A) . As shown in Fig. 3B however, the combination did not increase this further. The MCF-7Ca cells may require different treatment period with trastuzumab to exhibit similar effect. These results suggest that trastuzumab activated the aromatase transcription in ERadependent manner in LTLT-Ca cells.
Trastuzumab amplified mitogenic effects of estradiol in vitro and in vivo. E 2 stimulation of MCF-7Ca cells resulted in a typical biphasic dose-response curve where maximum stimulation occurs at a concentration of f10 À9 mol/L (Fig. 3C ). In contrast, as reported in our earlier studies, proliferation of LTLT-Ca cells is not stimulated by E 2 (1, 27) . However, when pretreated with trastuzumab (100 Ag/mL) for 72 hours, LTLT-Ca cells exhibited a marked stimulation of proliferation at concentrations of 10 À12 to 10 À7 mol/L when compared with E 2 alone (P < 0.0001). In addition, when MCF-7Ca cells were pretreated with trastuzumab, E 2 -stimulated proliferation was increased at concentrations of 10 À11 to 10 À10 mol/L (P = 0.02 and 0.03, respectively). The results suggest that inhibition of Her-2 restores ERa and E 2 sensitivity and that Her-2 is a negative regulator of ER. Pretreatment of MCF-7Ca, MCF-7, and LTLT-Ca cells with trastuzumab for 24 hours also increased aromatase activity in a dose-dependent manner (Fig. 3D) . At the same time, aromatase protein expression was up-regulated by trastuzumab in a dosedependent manner along with ERa (Fig. 4A) . Trastuzumab caused an increase in the aromatase activity of MCF-7, suggesting that trastuzumab influences endogenous aromatase. To investigate whether suppressing Her-2 resulted in up-regulation of ERa and aromatase was limited to LTLT-Ca cells, we carried out the same experiment with ER-negative and Her-2-positive SKBr-3 cells. The results were similar, confirming that inhibition of Her-2 results in increased aromatase activity (Fig. 3D, inset) and ERa up-regulation (data not shown). However, this effect was not seen in ER-negative and Her-2-negative MDA-MB-231 cells (data not shown). Trastuzumab did not bind competitively to ERa (Fig. 4B) , suggesting that the stimulatory effects were ERa dependent, not due to intrinsic estrogenic properties of trastuzumab. In addition, when MCF-7Ca cells were cotreated with increasing doses of trastuzumab for 24 hours followed by 1 nmol/L E 2 for 1 hour, transcriptional activity of ERa was found to be up-regulated in a dose-dependent manner. This increase was found to be higher than E 2 (1 nmol/L) treatment alone (Fig. 4C) .
The measurement of uterine weight is a useful bioassay that correlates with the levels of circulating estrogens in the body of the mice. The uteri of mice bearing LTLT-Ca xenografts treated with trastuzumab were removed and weighed at the completion of the experiment. Trastuzumab induced a statistically significant (P = 0.001) dose-dependent increase in uterine wet weight compared with controls (Fig. 4D) . Increased uterine weight suggests that cotreatment with trastuzumab acts to enhance ERa and effects of E 2 on the uterus. Furthermore, increased tumor aromatase activity suggests that trastuzumab increases E 2 synthesis from D (Fig. 5A) . The growth rate of control tumors (D 4 A, 100 Ag/d) was bi = 0.17 F 0.1, which was not statistically different from that of tumors in mice treated with trastuzumab (bi = 0.19 F 0.14) over the first 7 weeks. The mice in both these groups (control and trastuzumab) were sacrificed at week 7 due to large tumor volume. The tumors and uteri of the treated mice were removed, weighed, and stored at À80jC for any additional analysis. The tumor weights (Fig. 5B) of control (1.37 F 0.57 g) and trastuzumab (2.68 F 0.57 g) were not statistically different (P = 0.14). However, trastuzumab treatment alone was significantly less effective than other treatments [versus letrozole (P = 0.0009) or versus trastuzumab plus letrozole (P = 0.0001)].
As shown in Fig. 5C , uteri in mice treated with trastuzumab weighed significantly more than those treated with D 4 A (P = 0.008). The increase in uterine weight again suggests amplified growthstimulatory effects of E 2 on cotreatment with trastuzumab.
Combination of trastuzumab plus letrozole is more effective than either drug alone in letrozole-refractory tumors. As shown in Fig. 5A , combination of letrozole plus trastuzumab was effective in reducing the tumor growth rate (bi = À0.04 F 0.04 over weeks 0-15; bi = 0.28 F 0.06 over weeks [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . However, the combination was no more effective than letrozole as single agent (bi = À0.01 F 0.02 over weeks 0-15; bi = 0.1 F 0.08 over weeks [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Letrozole inhibited the growth of these tumors for a prolonged period (13 weeks). Nevertheless, tumors ultimately began to grow on continued treatment and had doubled in volume by week 15. At this time, the mice were subdivided into three groups: (a) trastuzumab, 5 mg/kg/wk (two doses; n = 10); (b) letrozole, 10 Ag/d, plus trastuzumab, 5 mg/kg/wk (n = 10); and (c) letrozole, 10 Ag/d (n = 10). The experiment was terminated on week 28. Tumors in mice switched to combination therapy following letrozole resistance responded better than combination treatment from week 0 (P < 0.0001). This suggests that on letrozole resistance, the addition of trastuzumab to the treatment regimen is superior to combination therapy from the beginning. The growth rate of these tumors was significantly different from the tumors of mice that stayed on letrozole treatment (P = 0.008). Tumors treated with letrozole responded better when switched to letrozole plus trastuzumab than those kept on letrozole. Letrozole-refractory tumors switched to trastuzumab alone responded to the treatment only for the first 3 weeks (weeks [16] [17] [18] [19] but then began to regrow at the rate similar to that of the letrozole-treated mice (weeks 15-28; P = 0.97). Thus, on resistance to letrozole, the addition of trastuzumab was more effective than the switch to trastuzumab, suggesting that Her-2 inhibition extends sensitivity of letrozole.
Protein expression and activity of tumors treated with letrozole and trastuzumab alone or in combination. At 28 weeks (Fig. 5A) , tumors of mice bearing MCF-7Ca xenografts were analyzed for expression of Her-2, p-MAPK, MAPK, aromatase, and ERa protein expression by Western blotting (Fig. 5D) . Treatment with trastuzumab increased ERa and decreased Her-2 and p-MAPK protein expression. In contrast, letrozole reduced ERa and increased Her-2 and p-MAPK levels. The combination of letrozole plus trastuzumab did not affect ERa levels and caused moderate increases in Her-2 and p-MAPK. The tumors of mice switched from letrozole to trastuzumab showed up-regulation of ER and down-regulation of Her-2 and p-MAPK compared with letrozole. This would be consistent with stimulation of growth due to release from aromatase inhibition, allowing estrogen production. In mice treated with letrozole and the addition of trastuzumab on tumor volume doubling, ERa levels were moderately increased, p-MAPK was down-regulated, and Her-2 was moderately reduced.
As shown in Fig. 6A , trastuzumab increased aromatase activity in the tumors, whereas letrozole inhibited aromatase activity. This increased activity was also accompanied by a 3.7-fold up-regulation Figure 4 . A, effect of trastuzumab treatment at various concentrations on protein expression of ERa, Her-2, and CYP-19 in MCF-7Ca cells. Expression of proteins was examined using Western immunoblotting as described in Materials and Methods. Blot shows ERa at 66 kDa, CYP-19 at 55 kDa, Her-2 at 185 kDa, and h-actin at 45 kDa. The blots show a single representative of three independent experiments. The blots were stripped and reprobed for h-actin to verify equal loading. B, effect of trastuzumab treatment on binding affinity of estradiol to ERa in MCF-7Ca cells. The competitive binding study was performed as described in Materials and Methods. The difference between trastuzumab and control in the percent of radioactive estradiol bound to ERa was 18.053, which was not statistically significant (P = 0.4, using Kruskal-Wallis test and Dunn's multiple comparison). C, effect of trastuzumab treatment at various doses on transactivation of ERa in MCF-7Ca cells. The ERa transactivation assay was performed to measure transcriptional activation of ERa in MCF-7Ca cells, as described in Materials and Methods. The treatment with trastuzumab increased ERa activation in a dose-dependent manner. The differences between E 2 W control and trastuzumab treatment (100, 200, 400, and 1,000 Ag/mL) were À111.31 (c, P = 0.06), À156.23 (b, P < 0.01), À279.91 (*, P < 0.001), and À305.45 (*, P < 0.001) and 0.04 for E 2 . When combined with 1 Amol/L letrozole, 1,000 Ag/mL trastuzumab did not stimulate ERa activation. Letrozole treatment was not significantly different from the E 2 W control. One-way ANOVA with post-hoc Tukey-Kramer test (*, P < 0.05). D, effect of trastuzumab treatment at various doses on uterine wet weight of mice bearing LTLT-Ca xenografts. The mice bearing LTLT-Ca xenografts were treated with trastuzumab at varying doses for 12 wk, after which the uteri were removed and weighed. The mice in control group had a mean uterine weight of 6.4 F 2.2 mg, which was the lowest uterine weight (exact two-sided P = 0.008 by the Wilcoxon test) and significantly lower than in mice treated with 2, 10, and 20 mg of trastuzumab. The mean uterine wet weights ranged from 15.4 F 2.2 mg to 20.4 F 2.2 mg to 29.8 F 2.2 mg.
of aromatase protein expression (Fig. 5D) . The aromatase activity in the tumor samples from letrozole, letrozole plus trastuzumab, and letrozole switched to letrozole plus trastuzumab was found to be significantly lower than control (P < 0.001) or trastuzumab treatment (P < 0.001). The aromatase activity of tumors from letrozole switched to trastuzumab alone-treated mice was, however, not significantly different from control but significantly higher than letrozole alone (P < 0.01). However, aromatase protein expression in all these groups was not significantly different from control. The data suggest that letrozole maintains aromatase inhibition after prolonged treatment and switching to trastuzumab therapy removes the inhibitory effect of the AI on aromatase. Furthermore, tumors of mice treated with letrozole switched to letrozole plus trastuzumab show reduced aromatase activity, suggesting that addition of trastuzumab to letrozole did not interfere directly with aromatase inhibition by letrozole.
Trastuzumab increases transcriptional activation of ERA in MCF-7Ca xenografts. The in vivo ChIP assay was used to Figure 6 . A, effect of trastuzumab and letrozole alone or in combination on aromatase activity of MCF-7Ca xenografts. The tumors of mice treated with letrozole, trastuzumab, and the combinations were examined for aromatase activity as described in Materials and Methods. The activity of the enzyme after treatment is corrected for total protein amount in the tumors. Aromatase activity of MCF-7Ca xenografts treated with trastuzumab is significantly higher than control (*, P < 0.001). Aromatase activity of control is significantly higher compared with letrozole (P < 0.001), letrozole plus trastuzumab (*, P < 0.001), and letrozole switched to letrozole plus trastuzumab (*, P < 0.001). The aromatase activity of letrozole switched to trastuzumab was not significantly different from D 4 A-treated control but significantly higher than letrozole (c, P < 0.01). One-way ANOVA, Tukey-Kramer multiple comparisons test. B, effect of trastuzumab and letrozole alone or in combination on the ERa-mediated transcriptional activation in MCF-7Ca xenografts. The in vivo ChIP assay was performed as described in Materials and Methods. E 2 -induced recruitment of ERa to the DNA in MCF-7Ca xenografts. The blot shows histone H3 at 15 kDa and RNA polymerase II at 300 kDa. ChIP analysis was done using ERa antibody. Input indicates samples before immunoprecipitation. C, effect of trastuzumab and letrozole alone or in combination on the ERa-mediated transcriptional activation in MCF-7Ca xenografts. The in vivo ChIP assay was performed as described earlier.
Treatment-induced recruitment of ERa to the aromatase I.3/II and pS2 promoter in MCF-7Ca xenografts was examined by PCR. Input indicates samples before immunoprecipitation. The blot shows aromatase product at 317 bp and pS2 at 415 bp.
measure the effect of trastuzumab on transcriptional activation of ERa in MCF-7Ca xenografts. D 4 A-treated control and trastuzumab-treated tumors exhibited active transcription of ERa, as evidenced by recruitment of histone H3 and RNA polymerase II into the transcriptional complex (Fig. 6B) . The treatment of MCF-7Ca tumors with trastuzumab increased recruitment of ERa to the pS2 and aromatase I.3/II promoter (Fig. 6C) . These findings support in vivo tumor volume data and suggest that trastuzumab treatment in a hormone-sensitive breast cancer model is agonistic via its effects on Her-2 and hence the ER. As such, Her-2 inhibition without blockade of estrogen signaling in the clinical setting could be detrimental.
Discussion
Although AI letrozole is more effective and tumor growth is suppressed over an extended period compared with tamoxifen, eventually tumors become resistant to AI therapy (1). Previous results indicate that tumor growth is maintained by activating Her-2/MAPK signaling pathways in letrozole-resistant LTLT-Ca cells and letrozole-refractory tumors. In addition, ER expression is decreased and cells become insensitive to E 2 , suggesting a hormone-refractory phenotype. Our previous studies also indicated that the combination of letrozole with MAPK inhibitor PD98059 up-regulated ERa expression, consistent with the reports that hyperactivation of MAPK induces loss of ERa in breast cancer cells (1, 28) . Her-2 is overexpressed in about 25% to 30% of breast cancers and correlates with poor diseasefree survival and overall survival (29, 30) . With the development of trastuzumab, effective targeted treatment of Her-2-overexpressing cancers has been possible. Treatment with trastuzumab also resulted in up-regulation of ERa. We have shown that loss of ERa expression induced by MAPK hyperactivation is reversible as observed in findings of others (31) . Our studies show that trastuzumab by blocking Her-2 can reverse the suppression of ERa. To prevent development of letrozole resistance and restore hormone sensitivity of resistant cells, we used trastuzumab to inhibit the Her-2/MAPK pathway in the present study.
The combination of trastuzumab with letrozole reversed resistance to the AI and restored responsiveness of the tumors. However, this effect was limited to letrozole-refractory and Her-2-overexpressing cells and tumors. Trastuzumab alone was only effective for a brief period of 4 weeks in letrozole-refractory tumors. In the tumors with low Her-2 levels, the letrozole plus trastuzumab combination was no more effective than letrozole single agent. However, in Her-2-overexpressing tumors, trastuzumab plus letrozole was far superior in inhibiting tumor growth compared with either single agent (Fig. 5A) . These results suggest that trastuzumab restores sensitivity of LTLT-Ca cells to letrozole by inhibiting Her-2 and up-regulation of ERa. As such, blockade of the ERa pathway remains an essential component of tumor and cell growth inhibition. Up-regulation of intratumoral aromatase was also seen with trastuzumab treatment to make the cells more responsive to AIs.
In our current study, we have shown that inhibition of Her-2 with trastuzumab results in activation of ERa-mediated signaling pathway. Based on these data, we hypothesize that an inverse and compensatory relationship exists between Her-2 and ERa and inhibition of one pathway leads to activation of the other.
Several reports have suggested that translocation of ERa to the membrane may be responsible for the cross-talk with EGFR family members in endocrine-resistant phenotype (32) (33) (34) , whereas a few reports have also suggested that EGFR family transmembrane receptors such as Her-2 can translocate to the nucleus and act as transcription factors (35) (36) (37) (38) .
Studies performed in trastuzumab-resistant variants of breast cancer cell lines have indicated up-regulation of transforming growth factor a (TGFa) and vascular endothelial growth factor (VEGF; refs. 39, 40) . Interestingly, both VEGF and TGFa are estrogen-responsive genes (41) . These data are consistent with our results and suggest that Her-2 suppresses ERa, as resistance to trastuzumab is associated with up-regulation of ERa-responsive genes (39, 40) . Our studies show that trastuzumab alone was not an effective treatment strategy in this model and the data suggest that it is likely to be due to up-regulation of intratumoral aromatase and ERa. To distinguish whether up-regulation of ERa was a result of increased protein synthesis or reduced degradation, cells were treated with trastuzumab in the presence or absence of cycloheximide (translational inhibitor). Western immunoblotting analysis revealed that trastuzumab treatment increased ERa to a greater extent in the absence of cycloheximide, suggesting that trastuzumab modulates protein synthesis. However, even in the presence of cycloheximide, ERa protein was up-regulated by trastuzumab treatment, suggesting that trastuzumab treatment affects protein degradation as well (data not shown). In addition, RT-PCR analysis revealed that ERa mRNA expression is increased with trastuzumab treatment in a dose-dependent manner (Fig. 2D) .
In agreement with our findings, clinical studies have shown that trastuzumab as single agent has promising effects in firstline treatment of f40% breast cancer patients (42) . However, the median duration of response is only f8 months. Furthermore, intrinsic or de novo resistance to trastuzumab in Her-2-overexpressing breast cancers has been reported. As the use of trastuzumab is now extended to adjuvant treatment of breast cancer, it is important to assess the molecular effects of trastuzumab on Her-2-overexpressing breast cancer cells and determine appropriate strategies for optimal treatment. Our studies clearly show the importance of inhibiting both estrogen signaling by AI letrozole and the growth factor receptor Her-2 pathway in overcoming resistance to therapy. However, if used for treatment of hormone-responsive tumors, trastuzumab may amplify estrogen signaling and stimulate tumor growth. The results indicate that inhibition of Her-2 via trastuzumab can restore the responsiveness of tumors to letrozole and trastuzumab, thus extending the use of AIs and delaying the need for chemotherapy.
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